Technology transfer / Localization · GCC · Announced 11 Nov 2026

Viatris → ADCAN Pharma

Viatris signed a cooperation agreement with Abu Dhabi's ADCAN Pharma to localise manufacturing of selected Viatris products in the UAE, witnessed by the Emirates Drug Establishment alongside its own MoU with Viatris.

Parties: Viatris (United States) → ADCAN Pharma (United Arab Emirates)

Value
Undisclosed
Territory
United Arab Emirates
Therapeutic area
Multi-therapy
Asset
Selected Viatris products (not named)
Announced
11 Nov 2026

Our analysis

Why this matters

Viatris and ADCAN Pharma signed a cooperation agreement, announced on 11 November 2026, to localise manufacturing of selected products from Viatris's portfolio in the UAE. It was signed by Tamer Elsallab, Viatris's Head of GCC & Levant Cluster, and ADCAN CEO Fokion Sinis, and witnessed by Dr Fatima Al Kaabi, Director-General of the Emirates Drug Establishment (EDE), which signed a separate MoU with Viatris at the same time. The products, volumes and timelines were not disclosed.

The deal adds a US-headquartered generics and established-brands major to ADCAN's run of 2026 localisation partners, which already includes Menarini, Elpen, Genepharm, Lotus, Inventia, MS Pharma and a manufacturing and trials MoU with M42.

The full analysis is free to read with a work email on this page.

Source: TradeArabia (via GDN)

More deals involving Viatris or ADCAN Pharma

Latest deals

All GCC deals → · All technology transfer / localization deals → · Browse all emerging-market pharma deals →